-
Article
Open AccessIntention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a U...
-
Article
Tumor inflammation-associated neurotoxicity
Cancer immunotherapies have unique toxicities. Establishment of grading scales and standardized grade-based treatment algorithms for toxicity syndromes can improve the safety of these treatments, as observed f...
-
Chapter
Release Assays and Potency Assays for CAR T-Cell Interventions
Chimeric antigen receptor (CAR) T-cells are considered “living drugs” and offer a compelling alternative to conventional anticancer therapies. Briefly, T-cells are redirected, using gene engineering technology...
-
Chapter
Point-of-Care Production of CAR-T Cells
CAR-T cells for clinical application are classified as advanced therapy medicinal products (ATMPs), and their manufacture is subject to laws and regulations governed by the European Medicines Agency (EMA) and ...
-
Article
Open AccessTunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction
Chimeric antigen receptor (CAR) T cells are a promising form of cancer immunotherapy, although they are often associated with severe toxicities. Here, we present a split-CAR design incorporating separate antig...
-
Article
Open AccessA primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats
Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets. Libraries generated from immunized animals offer the a...
